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In the search for effective therapeutic strategies, protein-based biologicals are under intense devel-
opment. While monoclonal antibodies represent the majority of these drugs, other innovative
approaches are exploring the use of scaffold proteins for the creation of binding molecules with
tailor-made properties. Ubiquitin is especially suited for this strategy due to several key character-
istics. Ubiquitin is a natural serum protein, 100% conserved across the mammalian class and pos-
sesses high thermal, structural and proteolytic stability. Because of its small size and lack of
posttranslational modiﬁcations, it can be easily produced in Escherichia coli. In this work we provide
evidence that ubiquitin is safe as tested experimentally in vivo. In contrast to previously published
results, we show that, in our hands, ubiquitin does not act as a functional ligand of the chemokine
receptor CXCR4. Cellular assays based on different signaling pathways of the receptor were con-
ducted with the natural agonist SDF-1 as a benchmark. In none of the assays could a response to
ubiquitin treatment be elicited. Furthermore, intravenous application to mice at high concentra-
tions did not induce any detectable effect on cytokine levels or hematological parameters.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Scaffolds
Targeted intervention at protein structures on cells or in serum
is the principle of therapeutic approaches using speciﬁcally devel-
oped or designed binders like monoclonal antibodies, soluble
receptor molecules and the new class of scaffold proteins. The
latter are based on natural or artiﬁcial protein molecules which are
engineered by randomizing surface exposed amino acid positions
to generate new binding properties to selected targets. In this ﬁeldseveral concepts are pursued. They range from small protein
domains such as the protein A domain (Afﬁbody, [1]), PDZ domains
[2] and ankyrin repeat proteins (Darpins, [3]), through small
full-length proteins, such as the commonly used thioredoxin scaf-
fold [4,5] to higher-molecular-weight beta-barrels and Ig-like
structures such as lipocalins (Anticalins, [6]), green ﬂuorescent
protein (GFP, [7]) and the T-cell receptor complex [8]. One partic-
ularly well-suited scaffold for therapeutic and other applications is
ubiquitin, a protein naturally occurring intracellular as well as in
serum [9].
1.2. Ubiquitin
Ubiquitin possesses unique featureswith respect to protein char-
acteristics, production and safety aspects. It has favorable biochem-
ical properties like a stable structure over a wide pH range, thermal
shifts or proteolytic degradation [10–12]. As a human serumprotein
ubiquitin exhibits low immunogenic potential when applied in
humans. Its sequence is fully conserved in mammals, enabling fast
development tracks due to dispensability of species-speciﬁc surro-
gate molecules during preclinical development. Ubiquitin can be
580 F. Job et al. / FEBS Open Bio 5 (2015) 579–593easily produced as soluble protein in high yields in the cytoplasm of
Escherichia coli [12]. Dimeric head-to-tail fusions of two derivatized
ubiquitin molecules are the basis for so called Afﬁlin compounds
currently under development [9].
Ubiquitin is present within the cell at concentrations in the low
lM range as free monomer as well as in conjugated form [13]. The
different states are mainly balanced by conjugation and deubiqui-
tinylation [14]. Intracellular ubiquitin has a half-life of several
hours. Its turnover is counter steered in the cell mainly by modu-
lation of intracellular ubiquitin pools and de novo synthesis
[15,16]. Cellular ubiquitin is involved in several functions in the
cytoplasm and the nucleus respectively [17]. In the cytoplasm it
is an important player in processes like autophagy, proteasome
mediated proteolysis, endocytosis of activated transmembrane
proteins, cargo sorting [18], innate immunity [19] and endoplasmic
reticulum associated degradation (ERAD, [20]). In the nucleus
ubiquitin is a key component for mRNA-transport, transcriptional
control, DNA damage tolerance and DNA repair [21]. The interac-
tions by which ubiquitin assists in the above mentioned processes
are manifold and include covalent as well as non-covalent binding
of ubiquitin to numerous cellular proteins. Non-covalent interac-
tions between ubiquitin and target proteins are of low afﬁnity with
KD values mostly in the high lM range [22,23]. With respect to
these interactions, several partially overlapping epitopes on the
surface of ubiquitin have been identiﬁed [24]. Covalent conjuga-
tion of ubiquitin to several proteins and to other ubiquitin entities
is of importance in proteolytic and non-proteolytic processes of the
cell. The initial step in this event is the activation of ubiquitin and
its transfer to the indicated protein. In this process which is driven
by a complex enzyme machinery (E1, E2 and E3 enzymes) the two
C-terminal glycine residues at positions 75 and 76 of ubiquitin play
a key role [25]. Modiﬁcation of ubiquitin at these positions via
amino acid exchange completely abolishes the transfer of ubiquitin
to proteins and the formation of polyubiquitin chains [26]. In
addition to conjugation to other proteins ubiquitin molecules are
activated and covalently attached to distinct lysine residues of
other ubiquitin entities. That way, polyubiquitinylated proteins
are formed. Currently, at least eight different types of ubiquitin
chains are known, with each individual linkage affecting distinct
cellular processes [27–31].
Ubiquitin is detected in serum of healthy humans in a concen-
tration of less than 100 ng/ml (<10 nM) [32]. An obvious source
might be the passive release from cells undergoing physiological
turnover [33], but there are also reports about ubiquitin release
from intact cells [34–36]. On the other hand uptake of ubiquitin
into cells of the hematopoietic system has been shown
[35,37,38]. The exact function of extracellular ubiquitin is still
under debate. A role in modulation of immune responses [39,40]
and conditions of inﬂammation is discussed [41,42], for a compre-
hensive review see Majetschak [43]. Experimental ﬁndings suggest
an inﬂuence on the ratios of the cellular components of the blood
[35] and recently on myocardial remodeling [44–46]. In this con-
text CXC motif chemokine receptor 4 (CXCR4) has been suggested
as a putative receptor for ubiquitin with an afﬁnity in the medium
nM range [47–50]. Signaling and function are described as being
similar but not equal to the hitherto known and well characterized
CXCR4 ligand stromal cell-derived factor 1 (SDF-1) [51–53].
1.3. CXCR4
CXCR4 is a typical class A G-protein coupled receptor broadly
expressed in the organism. It can be found especially in
hematopoietic cells but also many other cell types for example of
the central nervous system and the gastrointestinal tract. The bio-
logical functions of CXCR4 are crucial during development and
hematopoiesis [54–56]. It plays pleiotropic yet not fullyunderstood roles in the immune system and during tissue repair
processes [57–60]. Particular interest for CXCR4 as a drug target
is based on its role in HIV infection and metastatic diseases
[61–66]. The receptor is bound by its natural ligand SDF-1
(or chemokine (C–X–C motif) ligand 12) and a non-cognate ligand
MIF, migration inhibitory factor [67]. Receptor activation by
SDF-1 leads to anti-inﬂammatory and organ protective effects in
various disease models [68–71].
Because of these similarities in the overall effects to those of
ubiquitin [72–75], CXCR4 was discussed as a possible receptor for
ubiquitin in the literature [43,76,77]. In this paper we challenge this
hypothesis and present signiﬁcant results elucidating the signaling
competence of ubiquitin via different branches of the complex
CXCR4 downstream interaction network compared to the natural
ligand SDF-1. Neither in cells naturally expressingCXCR4nor in cells
transfected with the CXCR4 gene ubiquitin dependent CXCR4
activity could be demonstrated. Furthermore comprehensive data
concerning the in vivo application of ubiquitin are discussed.2. Material and methods
2.1. Production and puriﬁcation of ubiquitin proteins
Human ubiquitin for biodistribution and toxicity studies was
produced with an F45W substitution [12] in E. coli. The cDNA of
ubiquitin was subcloned into pSCIL008 expression vector and
expressed in E. coli JM83 cells (DSMZ). After cell harvest and dis-
ruption via ultrasonication, cell lysate was heat denatured for
5 min at 75 C in a water bath. Precipitated protein was removed
and the supernatant was diluted in 50 mM sodium acetate pH
5.0 and loaded onto a SP-Sepharose FF column. Elution was per-
formed by a sodium chloride gradient in 50 mM sodium acetate
pH 5.0. Fractions of interest were pooled and puriﬁed via a Q
Sepharose FF. The ﬂow through was applied onto a SP Sepharose
HP column and protein of interest was eluted by sodium chloride
gradient in 50 mM sodium acetate pH 5.0.
A pharmacokinetic study of ubiquitin was realized using com-
mercially available protein from R&D Systems (U-100H).
The genetic construct of di-ubiquitin was obtained via head to
tail fusion of the DNA fragments of two F45W ubiquitin monomers.
Di-ubiquitin was expressed from the expression vector pET20b
(Novagen) in E. coli Nova Blue (DE3) cells. After cell disruption,
solid (NH4)2SO4 was added to 40% saturation. Precipitated protein
was removed and the supernatant was applied to a Phenyl
Sepharose HP column. Elution was performed by (NH4)2SO4 gradi-
ent in 50 mM Tris/HCl, 1 mM EDTA, pH 7.5. Fractions containing
the target protein were pooled and applied to a SP Sepharose HP
column after cross-ﬂow ﬁltration in 50 mM acetic acid/NaOH,
1 mM EDTA, pH 5.5. Fractions of di-ubiquitin eluted in a sodium
chloride gradient were concentrated and applied to a Superdex
75 prep grade column equilibrated in phosphate-buffered saline
(PBS) for removal of monomeric ubiquitin fragments. Fractions
containing the homogeneous target protein were concentrated,
applied to a Q Sepharose FF anion exchange column and collected
in the ﬂow through.
Puriﬁed preparations of ubiquitin and di-ubiquitin were ﬁltered
through sterile 0.2 lm polyethersulfone disc ﬁlters (Millipore) and
stored at 80 C.
2.2. Protein analytics
Analytical size exclusion chromatography (SE-HPLC) was carried
out on a Superdex 75 Tricorn 10/300 column (GE Healthcare) cou-
pled to an Ultimate 3000 SD chromatographic system (Dionex
GmbH, Idstein, Germany). PBS containing 0.05% sodium azide as
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masses were estimated by comparison with the elution proﬁle of a
BioRad gel ﬁltration standard mix (BioRad). Reversed-phase chro-
matography analysis was carried out using a PLRP-S column
(300 Å, 5 lm, 250 mm  4.6 mm; Agilent) with an eluent system
of 0–80% 2-propanol in 0.1% triﬂuoroacetic acid, a ﬂow rate of
0.8 mL/min, and a column temperature of 65 C. Endotoxin content
was measured using the Endosafe-PTS™ system (Charles River).
The amount of residual E. coli host cell protein in puriﬁed protein
preparations was analyzed using a commercially available ELISA
kit (Cygnus Technologies).
2.3. Radio labeling and analytics
Ubiquitin was radio iodinated directly via Iodogen method [78].
In brief, 100 lg of protein and 180–200 lCi of Na125I-solution
(6.67–7.4 MBq, Perkin Elmer) were added to a reaction vial coated
with 50 lg of Iodogen. The mixture was incubated for 20 min at
room temperature followed by puriﬁcation via gel ﬁltration
(Sephadex G25, PD10) and elution with PBS. An alternative labeling
was performed for ubiquitin and di-ubiquitin by an indirect iodina-
tion method using N-succinimidyl 3-(125iodo)-benzoate (125I-SIB)
as iodo-precursor [79]. For this reaction, 125I-SIB and the protein
of interest were added to a reaction vial in a molar ratio of between
1/20 and 1/30, followed by pH adjustment to pH 8.5 using borate
buffer. The mixture was stirred at 4 C for 20 min and puriﬁed
accordingly.
Radio chemical purity was analyzed by instant thin layer chro-
matography (ITLC, Agilent Technologies). Purity of labeled proteins
was determined by analytical size exclusion chromatography with
radio detection. Serum stability was tested by incubation of the
proteins in 90% mouse serum at 37 C over 16 h followed by ITLC
and SE-HPLC analyses with radio detection.
2.4. Regulatory and husbandry
All in vivo studies were performed at qualiﬁed contract research
organizations under attendance of Scil Proteins scientists.
Biodistribution and pharmacokinetic studies were performed at
Chelatec SAS (France) and carried out in strict accordance with the
recommendations of the European Guide for the Care and Use of
Laboratory Animals (2010/63/EU). The protocol was approved by
the Committee on Ethics of Animal Experiments (CEEA PdL n6,
France).
Toxicity studies on ubiquitin and di-ubiquitin were performed
in strict accordance to the recommendations of the German
Guide for Use of Animals for Research Purposes (German
Protection of Animals Act, 18.05.2006, EU Directive 86/609). The
toxicity study on ubiquitin was conducted by Bayer Healthcare
AG (Wuppertal, Germany) and approved by the State Ofﬁce for
Nature, Environment and Consumer Protection of
Nordrhein-Westfalen in Recklinghausen, Germany (Permit
Number: AZ 9.93.2.10.43.07). The toxicity study on di-ubiquitin
was performed at the Laboratory of Pharmacology and
Toxicology GmbH & Co. KG (LPT, Hamburg, Germany) and
approved by the Public Authority for Health and Consumer
Protection in Hamburg (Permit Number: V 1307-591-00.33).
According to the German Basic Law (article 20a, 01.08.2002)
animal protection is an explicit constitutional aim. The ethical
tenability of animal studies in fundamental research is assessed
and approved by the authorities (referred to above) with their
own ethical advisors or committees. An additional ethical
committee is not stipulated.
Generally all efforts were made to minimize suffering of the
animals. Animals were allowed to acclimatize for at least one
week. During acclimatization phase animals were inspected on adaily basis for physical welfare. Free access to food (certiﬁed com-
mercial diet) and water was provided ad libitum. Animals were
housed under standard conditions of 20 ± 2 C temperature, a
humidity of 55 ± 5% and a light/dark cycle of 12 h rhythm by a
maximum of four (mice) and group wise per cage or individually
(rats). At the day of dosing, animals were weighed and examined
for physical abnormalities. Toxicity studies were performed as
blinded studies whilst PK and biodistribution studies were
non-blinded. Generally, in all in vivo studies animal allocation
was performed by body weight stratiﬁcation and randomization
by block design. Only healthy animals were included in the studies.
After the end of the studies, all animals were anesthetized under
diethyl ether anesthesia or by an intraperitoneal injection of keta-
mine hydrochloride and xylazine hydrochloride in PBS followed by
rapid sacriﬁce by exsanguination.
2.5. Biodistribution studies of ubiquitin and di-ubiquitin
For biodistribution experiments of 125I-ubiquitin, 3 male Wistar
rats (7 weeks of age, mean body weight 133 g; Janvier Laboratory,
France) were treated by an intravenous slow bolus injection of
radio iodinated ubiquitin into the tail vein. The protein formulated
in PBS was administered at a dose of 355 nmol/kg, a volume of
3 ml/kg and at a speciﬁc activity of 0.13 mCi/kg.
Biodistribution of 125I-SIB-labeled di-ubiquitin was performed
using a total of 12 female CD1 mice (7 weeks of age, mean body
weight 25 g; Charles River, France). Animals were divided into 4
groups (n = 3), equivalent to the different termination time points.
Radiolabeled di-ubiquitin in PBS was injected into the tail vein at a
dose of 11.4 nmol/kg, a volume of 5 ml/kg and at a speciﬁc activity
of 0.4 mCi/kg. Of three groups blood samples were collected at dif-
ferent time points (5 min, 1 h and 3 h) post-injection from the
saphenous vein of non-anaesthetized mice. Bleedings were per-
formed in a staggered regime with one bleeding time point for
each mouse and consistent bleeding time points of the animals
within a group. Blood was collected in Microvette tubes with clot-
ting activator (Sarstedt, Nürmbrecht, Germany) for serum prepara-
tion. For analysis of excretion balance and recovery of di-ubiquitin,
3 mice were individually housed in metabolic cages over 16 h.
At time of sacriﬁce (t = 15 min for 125I-ubiquitin treated group;
t = 0.5 h, 2 h, 8 h and 16 h for 125I-SIB-di-ubiquitin-treated groups),
blood was collected in Microvette tubes with clotting activator.
Subsequently, the animals were anesthetized by an intraperitoneal
injection of ketamine hydrochloride and xylazine hydrochloride in
PBS followed by rapid sacriﬁce by exsanguination via intracardiac
puncture. Organs of interest were excised, rinsed of residual blood,
weighed and counted in a gamma counter (Wallace Wizard 2470,
Perkin Elmer). Whole blood and serum radioactivity as well as
urine and feces radioactivity were measured accordingly.
Radioactivity was calculated as percent of injected dose (% ID)
per g tissue and % ID/total tissue.
2.6. Pharmacokinetic studies of ubiquitin
For a PK study of ubiquitin, a total of 16 female CD1 mice
(7 weeks of age, mean body weight 25 g; Charles River, France)
were used. Animals were divided into four groups (n = 4).
125I-SIB-labeled ubiquitin was injected into the tail vein at a dose
of 23.5 nmol/kg, a volume of 4 ml/kg and at a speciﬁc activity of
2 mCi/kg. Blood samples were collected from the submandibular
vein of non-anaesthetized mice at seven bleeding time points
post-injection (1 min, 5 min, 10 min 15 min, 30 min, 45 min and
60 min). Bleeding was performed group wise in a staggered regime
with a maximum of two bleeding time points for each animal,
approximately 30 min between the bleedings and consistent
bleeding time points of the animals within a group. Blood was
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corresponding serum fractions were analyzed in a gamma counter.
Radioactivity was calculated as % ID/g tissue and quantiﬁed as
equivalent of protein provided as ng/total blood or serum and
ng/g blood or serum.
2.7. Toxicity studies
For a subacute toxicity study of ubiquitin and a pilot toxicity
study of di-ubiquitin, Wistar rats were obtained from Harlan
Winkelmann GmbH (Germany) and Charles River (Germany),
respectively.
For a subacute toxicity study of ubiquitin, a total of 20 Wistar
rats (10 male and 10 female, 6 to 8 weeks of age, body weight
range: 172–191 g/male rats, 142–160 g/female rats) were divided
into two groups (n = 5 female and 5 male). Animals were assigned
to their groups by randomization according to their body weight
using a software application. Rats exhibiting extreme body weights
were excluded from randomization. In the ubiquitin treatment
group, animals were intravenously injected into the tail vein with
a daily dose of 3 mg PBS-formulated ubiquitin per kg body weight
at a dosing volume of 5 ml/kg over 14 days. In the control group,
animals were treated with PBS vehicle accordingly. Inspections
on morbidity and mortality were performed twice daily. Clinical
signs and body weights were recorded once daily prior to each
treatment. Individual food and water intake were determined
weekly. On day 15, 24 h after the last treatment, all animals were
sacriﬁced by exsanguination under diethyl ether anesthesia.
Animals were inspected and their organs and tissues were sub-
jected to thorough gross pathological examination. Organs were
weighed and ﬁxed for histopathological examinations. Heart, liver,
kidneys, spleen, thymus and popliteal lymph node were embedded
in Paraplast (Sigma) followed by subsequent sectioning. All slices
were stained with hematoxylin and eosin (H&E). Cryo cuts
obtained from the liver were stained with Oil Red O (ORO).
Clinical laboratory investigations on blood were performed on
the day of sacriﬁce. Determination of hemoglobin, blood leuko-
cytes, erythrocytes, reticulocytes, thrombocytes as well as white
blood cell differentiation and calculations of hematocrit, MCV,
MCH, MCHC were performed using ADVIA 120 Hematology
System (Siemens). Blood coagulation was determined using a
Hepatoquick test kit (Roche) and a ball coagulometer KC10
(Amelung). For determination of blood alkaline phosphatase,
alanine aminotransferase, aspartate aminotransferase, gamma
-glutamyltransferase, creatine kinase, lactate dehydrogenase,
glutamate dehydrogenase, albumin total protein, creatinine, urea,
glucose, inorganic phosphate, triglyceride and total bilirubin
commercially available test kits were used. Electrolytes (sodium,
potassium, calcium) were determined by ﬂame photometric assays
using a ﬂame photometer EFUX 5057 (Eppendorf-Netheler-Hinz
GmbH). Chloride was estimated by coulometric analysis on a
Chloridmeter 50 (Kreienbaum Wissenschaftliche Meßsysteme
e.K.). The study was performed in a GLP-certiﬁed laboratory at
Bayer Healthcare AG (Germany) according to established proce-
dures and protocols. Statistical evaluations on body and organ
weight as well as food and water intake were done using the
Dunnett-test in connection with a variance analysis. Evaluation
of biochemical parameters was performed primarily by analyses
of variance followed by a Dunnett-test. For all tests SAS routines
were applied. For evaluation of statistical different effects the dose
groups were compared to the treatment groups of the same
gender.
For a pilot toxicity study of di-ubiquitin, a total of 32Wistar rats
(16 male and 16 female, body weight range: 145–186 g/male rats,
132–156 g/female rats) were divided into 4 groups (n = 4 male and
4 female). Animals were assigned to their groups by randomizationaccording to their body weight using a software application.
Animals of groups 2–4 were intravenously injected into the tail
vein with a single slow bolus injection of PBS-formulated
di-ubiquitin at a dose of 3 mg, 17 mg or 100 mg per kg body weight
in a volume of 8 ml/kg. In the control group 1 animals were treated
with PBS vehicle accordingly. Animals were observed for mortality
and clinical signs throughout the day after test item administra-
tion. At predose and 0.5 h, 6 h and 24 h post administration blood
samples were taken from the retrobulbar venous plexus under
isoﬂurane anaesthesia and transferred to hematological examina-
tions (see above but excluding coagulation). Cytokine levels (IL-2,
IL-12 and IFN-gamma) were determined in blood serum via Bead
Array on a Cytomics FC 500 (Beckman Coulter GmbH). 24 h post
administration animals were sacriﬁced under ether anesthesia by
exsanguination. Animals were inspected, weighed and their organs
and tissues were subjected to thorough gross pathological exami-
nation. The study was performed at the Laboratory of
Pharmacology and Toxicology GmbH & Co. KG (LPT, Germany)
based on the OECD principles of good laboratory practice.
Statistical analyses of potential signiﬁcant effects between the
treatment groups and the control group of the same gender were
performed using the multiple t-test based on Dunnett and a limit
of p < 0.01 and p < 0.05.
2.8. Cells and reagents
HEK293 (DSMZ) and COS-7 (DSMZ) cells were maintained in
DMEM (Lonza) supplemented with 10% FBS (Gibco). THP-1
(DSMZ where not speciﬁed and ATCC as indicated) and Jurkat
(DSMZ) cells were cultivated in RPMI1640 (Lonza) supplemented
with 10% FBS (Gibco).
2.9. Cloning
The CXCR4 gene was purchased from Thermo Scientiﬁc and PCR
ampliﬁed with speciﬁc primers: pCDNA3-CX forward 50-GCA TGA
ATT CGC CAC CAT GGA GGG GAT CAG TAT ATA C-30 and
pCDNA3-CX reverse 50-GCA TCT CGA GTT AGC TGG AGT GAA AAC
TTG AAG ACT C-30. PCR fragments were digested with EcoRI and
XhoI (NEB) and ligated into pCDNA3 (Life Technologies) digested
with the same enzymes using the Rapid Ligation kit (Roche).
Ligation reactions were puriﬁed with the MinElute Reaction
Cleanup kit (Qiagen) and transformed into E. coli XL1 blue cells
(Agilent). After antibiotic selection a positive clone was sequence
veriﬁed and propagated for plasmid preparation with the
QIAﬁlter Plasmid Midi kit (Qiagen).
2.10. FACS analysis
CXCR4bindingwasanalyzedusingCXCR4expressing suspension
cell lines THP-1 and Jurkat. 2  105 cells were suspended in 100 ll
cold PBS containing indicated N-terminally labeled FITC-Ubiquitin
(R&D Systems) concentrations. Speciﬁc binding of FITC-ubiquitin
to CXCR4 was measured in the presence of a 30-fold molar excess
of unlabeled ubiquitin (Sigma). Samples were incubated 30 min at
4 Candwashed twicewith500 ll coldPBS. Fluorescence intensities
of 1  104 cells were determined using ﬂow cytometry
(FACSCalibur, BD Bioscience) at 490 nm wavelength.
Furthermore, about 8  105 HEK293 cells in DMEM/HamsF12,
10% FBS were cultivated in 12well plates and were allowed to grow
to 80% conﬂuence at 37 C. Cells were transiently transfected with
1.28 lg pVITRO2-CXCR4, 0.32 lg chimeric G-protein G
alphaD6qi4myr cDNA and 4.8 ll Metafectene per well in 1 ml culti-
vation medium overnight. As control non-transfected cells were
maintained. 200 ll Trypsin/EDTA per well were used to detach
HEK293 cells. 800 ll DMEM medium were pipetted to the cell
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trifuged for 2 min at 500g. Pellets were resuspended in 200 ll cold
PBS containing 1 lM FITC-ubiquitin or as positive control 1 lM
Alexa647-labelled SDF-1 (labelling of SDF-1 according to
NanoTemper L001 Monolith™ Protein Labeling Kit RED-NHS
instructions). Incubation was carried out for 30 min on ice and for
FACS analyzes (CyFLow ML, Partec) cells were washed twice
with cold PBS. Fluorescence intensities of 5  104 cells were
analyzed.
2.11. Calcium-ﬂux assay
Intracellular calcium mobilization was monitored using the
FLIPR 5 Calcium Assay Kit (Molecular Devices). 1.2  105 THP-1
or Jurkat cells were suspended in 200 ll RPMI-1640, 2% FBS and
seeded into a 96 well plate (black/clear bottom). An equal volume
of Kit component A (calcium sensitive dye and masking dye) was
added to the cells and the samples were incubated for 1 h at
37 C and 5% CO2. Relative ﬂuorescence signals were measured
simultaneously to automated ubiquitin or SDF-1 (PeproTech)
administration to the cells using a FlexStation3 microplate reader
(Molecular Devices). Dose response curves were collected for ubiq-
uitin concentrations ranging from 1010 to 106 M (ubiquitin
Sigma) and from 5  106 to 2  105 (ubiquitin Sigma) and for
5  105 M (ubiquitin R&D Systems). For evaluation, signals
recorded after complete ligand addition were normalized to
RFU = 1 and t = 0. All curves were baseline corrected. Data were
obtained as triplicates in between two and four independent
experiments and progress curves are shown and calculated EC50
values are given as mean ± SEM.
2.12. cAMP-ELISA
cAMP levels were quantiﬁed using the cAMP complete enzyme
immunoassay kit, acetylated format (EnzoLifescience). The cAMP
competitive ELISA was performed according to the manufacturer’s
protocol. In brief, 5  105 THP-1 cells were incubated 15 min at
37 C with or without ubiquitin (Sigma), SDF-1 or mixtures of both
proteins in 100 ll PBS. Next the cells were centrifuged at 500g for
5 min. cAMP was extracted by lysing the cell pellets in 200 ll 0.1 N
HCl and incubating the samples for additional 20 min at room tem-
perature. Cellular debris was removed by centrifugation at 500g
for 5 min. 100 ll of the supernatant were used for the quantiﬁca-
tion of cAMP levels by ELISA. All incubation steps were performed
at room temperature. Signals were read out using a THERMO
Multiscan GO microplate reader at a wavelength of 405 nm.
Assays were repeated at least three times in triplicates and data
are shown as mean ± SEM.
2.13. cAMP reporter assay
HEK293 cells were transfected with pCDNA3-CXCR4 and
selected with 400 lg/ml G-418 (Merck). Stable cell pools were
then transfected transiently with pGL4.29 plasmid (Promega) con-
taining a CRE element using Fugene HD transfection reagent
(Promega) according to the manufacturer’s speciﬁcations. After
24 h cells were seeded in a 96 well microtiter plate (TPP) and
grown at 37 C, 5% CO2. 48 h after transfection 20 lM forskolin
(Merck) and respective compounds in indicated concentrations
were added to the cells and incubated for 1 h at 37 C, 5% CO2.
100 lM AMD3100 (Merck), a CXCR4 inhibitor, was applied
30 min prior to compound addition where stated. Subsequently,
cells were equilibrated at room temperature for 10 min and an
equal volume of One-Glo reagent (Promega) was added. After
10 min incubation at room temperature the luminescent signal
was read out in an Inﬁnite M200 plate reader (Tecan).2.14. Inositol phosphate accumulation assay
To investigate CXCR4 activation by SDF-1 and ubiquitin (Sigma,
F45W Scil Proteins), inositol phosphate accumulation assays with
transiently transfected COS-7 and HEK293 cells were performed
according to [80] with minor changes. Brieﬂy 9  104 HEK293 cells
in 500 ll DMEM/HamsF12, 10% FBS per well were cultivated in
poly-lysine coated 48 well plates. For COS-7 6  104 cells per well
were seeded in 500 ll DMEM, 10% FBS into 48 well plates. After
incubation overnight cells were transiently transfected with
0.32 lg pVITRO2-CXCR4, 0.08 lg chimeric G-protein
GalphaD6qi4myr cDNA [81] and 1.2 ll Metafectene (Biontex) per
well in 250 ll of the respective cultivation medium according to
the manufacturer’s protocol. Cells were incubated for 6 h or over-
night at 37 C and subsequently labelled with 0.3 lCi
3H-myo-inositol for at least 16 h and washed with 250 ll DMEM
containing 10 mM LiCl. Various concentrations of ubiquitin
(Sigma or F45W Scil Proteins) or SDF-1 [82] dissolved in 150 ll
DMEM/10 mM LiCl were added to the cells and incubated for 2 h
at 37 C. After medium aspiration, cells were lysed in 100 ll
0.1 N NaOH for 5 min at room temperature. 50 ll of 0.13 M formic
acid were added to the wells and the samples were subsequently
diluted 1:6 with IP-dilution buffer (5.0 mM Na-borate, 0.5 mM
Na-EDTA). Cell debris was removed with a truncated pipet tip.
IP3 amounts were determined by anion exchange chromatography
followed by a beta counter quantiﬁcation as described previously
[83]. Experiments with COS-7 cells were performed in duplicates
and with HEK293 cells in triplicates. For both cell lines at least
three independent data sets were generated. Data were normalized
to receptor activation in% and calculated EC50 values are given as
mean ± SEM.
2.15. Cell migration assay
CXCR4 expressing THP-1 and Jurkat cells were used to analyze
induction of chemotaxis triggered by ubiquitin (Sigma) or SDF-1.
In vitro cell migration was assessed using 96 HTS transwell plate
chambers (Sigma; pore size: 5 lm for Jurkat and 8 lm for THP-1
cells) as described earlier [47]. Brieﬂy, in the lower chamber
250 ll PBS with or without varying SDF-1 or ubiquitin concentra-
tions (1010–106 M) were loaded, whereas the upper chamber
contained 2  105 cells in 100 ll PBS. After 3 h of incubation at
37 C, 200 ll of the lower chamber were diluted 1:2 with 5 lg/ml
propidiumiodide and incubated for 10 min at room temperature.
Propidiumiodide staining enabled identiﬁcation of living cells that
had actively migrated to the lower chamber and were counted
using ﬂow cytometry analysis (FACSCalibur BD Bioscience). The
chemotactic index was calculated by dividing the number of
migrated cells towards a speciﬁc ligand concentration by the num-
ber of migrated cells against PBS (control). Data were collected as
triplicates in at least three independent experiments and shown
as mean ± SEM.
2.16. Ubiquitination assay
To check for the activity of all ubiquitin proteins (derived from
Sigma, R&D Systems or cloned and puriﬁed by Scil Proteins GmbH)
used within this study an in vitro ubiquitination assay was per-
formed. CHIP Ubiquitin Ligase Kit-Glow-Fold Substrate (R&D
Systems) was applied and all experimental steps were conducted
according to the manufacturer’s protocol. Brieﬂy, a mix of water,
E3 ligase reaction buffer, Mg2+-ATP solution, HSP40/HSP70 and
Glow-Fold™ substrate was heated for 7 min at 43 C and then
cooled for 10 min on ice. Afterwards, E1 and E2 enzyme and
CHIP were added. Beside the kit supplied ubiquitin (positive con-
trol) indicated ubiquitin proteins (each 300 lM) were analyzed.
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were incubated for 1 h at 37 C and terminated by the addition
of 5SDS–PAGE sample buffer containing DTT. Reactions were
heated 5 min at 90 C and afterwards loaded and run at 100 V,
2 h on a 10% TGX stain-free gel (Bio-Rad). The gel was activated
and imaged in the Gel Doc EZ Imager station (Bio-Rad). Proteins
were transferred to a PVDF membrane with the TransBlot turbo
system (Bio-Rad). Detection of ubiquitinated Glow-Fold™ sub-
strate was via western blot analysis using a-Glow-Fold™ primary
antibody and HRP-labeled secondary antibody (R&D Systems,
HAF017) according to the kit protocol.
3. Results
3.1. Protein preparation
Ubiquitin and di-ubiquitin were produced by heterologous
expression in E. coli and puriﬁed by a series of chromatographic
steps. The obtained preparations were homogeneous, as judged
by Coomassie-stained SDS-PAGE and SE-HPLC and more than 98%
pure by RP-HPLC. For di-ubiquitin no response in an endotoxin
assay could be observed up to a sensitivity of 0.007 EU/mg protein.
Host cell protein content was determined to be 32 ppm. Endotoxin
in the ubiquitin preparation was determined at 0.33 EU/mg.
For the investigation of biodistribution and pharmacokinetics,
ubiquitin proteins were directly iodinated on tyrosine side chains
or indirectly iodinated on lysine residues. The labeling efﬁciency
of the proteins was between 60% and 80%. Labeled proteins were
more than 95% pure as determined by SE-HPLC with more than
99% protein associated radio label.Fig. 1. Blood clearance of ubiquitin. (A) 125I-SIB-labeled ubiquitin (R&D Systems) or (B) F4
CD1 mice. Blood samples of indicated bleeding time points were collected from three
radioactivity was calculated as % ID/g tissue. Error bars represent SD.
Fig. 2. Blood and serum accumulation of ubiquitin. (A) 125I-SIB-labeled ubiquitin (R&D
7 weeks old, female CD1 mice. Blood samples of indicated bleeding time points were colle
a gamma counter, radioactivity was calculated and quantiﬁed as equivalent of protein p3.2. Blood/serum analysis and pharmacokinetics
In vitro stability analysis of 125I-SIB-labeled proteins incubated
for 16 h at 37 C in 90% mouse serum revealed no dehalogenation
as determined by ITLC. In addition, SE-HPLC analyses of serum
incubated proteins provided a single peak eluting at a retention
time comparable to the proteins stored in PBS (Fig. S1A and B).
Determination of radioactivity of ex vivo blood samples
obtained from CD1 mice treated with 125I-SIB-ubiquitin (Fig. 1A)
and 125I-SIB-di-ubiquitin (Fig. 1B) showed that both proteins are
rapidly cleared from the circulation. For 125I-SIB-ubiquitin a
half-life of 23.6 min at a basal serum level of 24.0 ng/ml was
determined.
Comparison of radioactivity measured in whole blood and the
corresponding serum samples revealed accumulation of both
proteins in the serum (Fig. 2A and B), i.e. there is no measurable
cellular uptake of ubiquitin from the serum.
3.3. Biodistribution
Biodistribution studies in healthy animals were conducted to
provide information on potential ubiquitin accumulation in main
organs as well as organs and tissues of expected relevance due to
their known CXCR4-expression. Initial tissue distribution of ubiq-
uitin determined 15 min after intravenous administration into
Wistar rats was performed using directly labeled protein
(Table 1). To reduce the risk of in vivo dehalogenation and the
potential for related tissue background radio activity mediated
by enzymatically released and metabolized 125Iodide, especially
when evaluating biodistribution over several hours5W di-ubiquitin (Scil Proteins) was injected into the tail vein of 7 weeks old, female
non-anaesthetized mice. After analysis of blood and serum in a gamma counter,
Systems) or (B) F45W di-ubiquitin (Scil Proteins) was injected into the tail vein of
cted from three non-anaesthetized mice. After analysis of whole blood and serum in
rovided as ng/total blood or serum. Error bars represent SD.
Table 1
Distribution of 125I-ubiquitin in Wistar rats after 0.25 h in % ID/g tissue.
125I-ubiquitin % ID/g tissue
Blood 1.02 ± 0.07
Heart 0.48 ± 0.02
Lungs 1.06 ± 0.13
Spleen 0.29 ± 0.02
Kidneys 33.07 ± 3.57
Liver 0.35 ± 0.04
GI tract 0.27 ± 0.01
Brain 0.04 ± 0.01
Table 2
Distribution of 125I-SIB-di-ubiquitin in CD1 mice at different time points in % ID/g
tissue.
125I-SIB-di-ubiquitin 0.5 h 2 h 8 h
Blood 2.16 ± 0.40 0.22 ± 0.08 0.01 ± 0.01
Heart 0.78 ± 0.18 0.06 ± 0.02 0.01 ± 0.01
Lungs 2.73 ± 0.70 0.24 ± 0.10 0.04 ± 0.02
Spleen 1.09 ± 0.37 0.16 ± 0.06 0.04 ± 0.02
Kidneys 57.73 ± 7.20 4.74 ± 1.64 0.07 ± 0.02
Liver 2.12 ± 0.49 0.27 ± 0.51 0.03 ± 0.02
GI tract 2.02 ± 0.61 0.69 ± 0.32 0.02 ± 0.01
Brain 0.07 ± 0.01 0.006 ± 0.003 0.003 ± 0.004
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CD1 mice (Table 2).
Tissue distribution of 125I-ubiquitin and 125I-SIB-di-ubiquitin
showed that, except for the kidneys, no relevant accumulation of
either protein is observed in main organs at any time after intra-
venous injection. 125I-SIB-di-ubiquitin is cleared from the circula-
tion and from organs revealing organ/blood ratios <1. For
125I-ubiquitin and 125I-SIB-di-ubiquitin 15 min or 30 min
post-injection, total radioactivity of main organs, again kidneys
excluded, accounted for approximately 15% and 8% of the injected
dose, respectively. At the same time, 46% and 16% of injected dosesFig. 3. Blood cell numbers and IFN-gamma levels after ubiquitin treatment. (A) In a subac
with F45W ubiquitin (Scil Proteins, grey bars) or the vehicle control (white bars) were ana
counts from blood samples of male rats, error bars represent SD. (B) In a pilot acute toxicit
of F45W di-ubiquitin (Scil Proteins, grey bars) or the vehicle control (white bars) were an
bars represent SD. (C and D) IFN-gamma levels of male (C, n = 4) and female (D, n = 4) ra
points. Error bars represent SD.of ubiquitin and di-ubiquitin were found in the kidneys. Excretion
analysis revealed renal elimination as main path for di-ubiquitin
clearance with 96.0% of radioactivity found in urine and 0.7% of
radioactivity detected in feces 16 h post-injection. The carcass,
constituting approximately 90% of the total animal weight and rep-
resenting the sum of the remaining tissues, e.g. skin, fat and bones,
accounted for 32% and 37% of the injected dose of the proteins at
15 min or 30 min post-injection. Independent biodistribution stud-
ies in mice pointed to an accumulation of less than 0.5% ID/g in
these tissues at 2 h post-injection. Radioactivity in spleen was
determined at 0.29% ID/g at 15 min post-injection of
125I-ubiquitin and 1.09% ID/g at 30 min post-injection of
125I-SIB-di-ubiquitin decreasing over time.
3.4. Toxicity studies
Toxicity studies in rats were performed to provide information
on potential adverse effects after intravenous administration of
ubiquitin and di-ubiquitin. A subacute toxicity study, based on
daily intravenous dosing of 3 mg/kg ubiquitin over 2 weeks
in Wistar rats, revealed no evidence for a treatment-related
statistically signiﬁcant effect on body weights, food and water
consumption. Hematological examinations did not point to
statistically signiﬁcant effects on blood cell counts (Fig. 3A) as well
as hemoglobin and blood coagulation. The same holds true for
clinical chemistry examinations. Macroscopic post-mortem
examinations did not point to pathological ﬁndings at the
examined organs and tissues. Gross pathological and treatment-
related changes were not recorded. Histopathological examinations
of speciﬁed organs revealed some spontaneous ﬁndings which
were evenly distributed between treatment and control groups
and thus were not treatment-related. Lack of speciﬁc organ toxicity
could be also veriﬁed for the kidney as organ of highest exposure
and excretion.
A single dose toxicity study of di-ubiquitin administered in a
dose range between 3 mg/kg and 100 mg/kg in rats revealed noute toxicity study blood samples of rats (n = 10/group, 5 male and 5 female) treated
lyzed and numbers of different blood cell types were determined. Bars represent cell
y study blood samples of rats (n = 8, 4 male and 4 female) treated with various doses
alyzed and numbers of lymphocytes were determined at indicated time points. Error
ts of B were determined with a bead array on a Cytomics FC 500 at indicated time
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adverse effects on physiological parameters were found. Cage side
observations of skin/fur, eyes, mucous membranes, respiratory and
circulatory systems, somatomotor activity, and behavior patterns
did not point to treatment-related effects. The treatment was well
tolerated and there were no signs of local irritations at the injec-
tion site. The faeces of all rats showed a normal consistency during
the entire experimental period. No premature deaths occurred dur-
ing the course of the study. Body weights determined at predose
and at day 1 did not point to statistically signiﬁcant alterations
between the treatment groups and the control group.
Hematological examinations of the treatment groups on erythro-
cytes, leukocytes, platelets, differential blood count including lym-
phocytes (Fig. 3B) and hemoglobin, each determined predose and
0.5 h, 6 h and 24 h post administration, did not reveal any
dose-dependent or time-dependent treatment-related changes.
However, as can be expected for multiple comparisons, individual
values at individual dosing groups or time points were found to
deviate signiﬁcantly from the control group. All of these values
remained within the normal range for the individual parameters
and where thus assessed as treatment-unrelated. Cytokine deter-
mination in serum samples at 0.5 h, 6 h and 24 h post-injection
did not point to a treatment-related increase of pro
-inﬂammatory cytokines. At any time point, IL-2, IL-12 (Fig. S2)
and IFN-gamma (Fig. 3C and D) serum levels remained within
the range of the control group serum levels of less than 4 pg/ml,
55 pg/ml and 40 pg/ml, respectively. Statistical comparison of
treatment groups versus vehicle-treated control group at the indi-
cated time point did not provide evidence for a statistically signif-
icant alteration of the assessed cytokines. Macroscopic
post-mortem examinations did not point to any treatment
-related pathological changes of the inspected superﬁcial and sub-
cutaneous tissues. Due attention was paid to organs of the thoracic
viscera i.e., thymus, lymph nodes and heart and to organs of the
abdominal viscera i.e., urinary bladder, gastrointestinal tract, stom-
ach and caecum without hints for treatment-related effects.
Examination of lungs, liver, kidneys, gonads, adrenal glands,
uterus, intra-abdominal lymph nodes and accessory reproductive
organs did not provide evidence for treatment-related effects on
their appearance or size. No pathological ﬁndings were detected
at any examined organ.
3.5. Ubiquitin binding to CXCR4 expressed on eucaryotic cells
Our in vivo experiments did not suggest any evidence for speci-
ﬁc ubiquitin accumulation on the tested hematopoetic cells.
However, previously it has been reported that extracellular ubiqui-
tin is able to bind to and activate the CXCR4 receptor present on
lymphocytic cell lines like THP-1 [48]. To corroborate our data
from the in vivo studies and relate them to the existing literature
we sought to investigate the binding of ubiquitin to CXCR4 in
two relevant cell lines, THP-1 (Fig. 4A) and Jurkat (Fig. 4B). Cells
were incubated with 1 or 10 lM FITC-labeled ubiquitin and bind-
ing was assessed through FACS measurements. To account for
non-speciﬁc binding of FITC-ubiquitin to the cellular surface, unla-
beled ubiquitin was added in a 30-fold molar excess to compete for
speciﬁc binding. The addition of 10 lM labelled ubiquitin to both
CXCR4 positive cell lines resulted in a small shift of the cell popu-
lations towards higher ﬂuorescence intensities, whereas none or a
very weak shift was observed after incubation with 1 lM
FITC-ubiquitin in THP1 and Jurkat respectively. Binding at the
higher FITC-ubiquitin concentration was most likely non-speciﬁc,
as it could not be blocked with unlabeled ubiquitin and no
decrease in the FACS signal was detected under these conditions.
In addition, experiments with HEK293 overexpressing the CXCR4
were performed. Alexa Fluor 647 labelled SDF-1 showed increasedbinding to HEK293 cells after CXCR4 cDNA transfection (Fig. S3B),
whereas no FITC-ubiquitin binding to the receptor could be
detected (Fig. S3A). As a control, non-transfected HEK293 cells
were used. These results are in contradiction to reports claiming
that ubiquitin binds speciﬁcally to THP-1 or to
CXCR4-transfected HEK293 cells at the examined conditions [48].
3.6. Inﬂuence of ubiquitin on CXCR4-mediated calcium-ﬂux
To investigate the signaling of CXCR4 in response to the binding
of its two reported ligands, SDF-1 [84,85] and ubiquitin [47], we
measured intracellular calciumﬂuxes as part of the G-proteinmedi-
ated signal cascade. THP-1 and Jurkat cells were labeled with the
Calcium 5 ﬂuorophore and treated with a concentration series of
the two compounds in a FlexStation 3 (Molecular devices). This
instrument was especially designed to precisely measure the very
fast release of calcium ions indicated by an increase in ﬂuorescent
signal in real time. SDF-1 was effective in both cell lines
(Fig. 4C and D) with an EC50 of 9 ± 1.4 nM, which is in good agree-
ment with the existing literature [86]. In contrast, ubiquitin failed
to induce any change in ﬂuorescence signal intensity and accord-
ingly in the cytosolic calcium ion levels. The results were further
conﬁrmed by additional measurements at very high ubiquitin con-
centrations. Ubiquitin from two different suppliers was applied at
up to 20 or 50 lM on both cell types without eliciting any calcium
signal (Fig. S4). This supports the conclusion that ubiquitin has no
agonistic activity on the calcium ﬂux response in THP-1 and Jurkat
cells.
3.7. Impact of ubiquitin on intracellular cAMP levels
To further differentiate effects on the CXCR4 signaling cascade
we made use of a cAMP ELISA kit (Enzo life sciences).
Intracellular cAMP levels were quantiﬁed after incubation of the
respective cells with the CXCR4 ligand SDF-1 or ubiquitin at two
different concentrations, 1 lM and 100 nM. Since CXCR4 signals
through G alpha i proteins, ligand binding and activation of the
receptor should result in decreasing cAMP levels, which would cor-
respond to an increase in signal intensity in this speciﬁc ELISA
setup. Again, SDF-1 was able to decrease intracellular cAMP levels,
whereas ubiquitin had no effect on intracellular cAMP levels
(Fig. 5A). Because this is in contrast to already reported results,
we veriﬁed several sources of experimental variability: (i) a
THP-1 cell line from a different supplier (ATCC) revealed essen-
tially the same result (Fig. S5A). (ii) To account for differences in
incubation times we performed a time course experiment with
increased incubation times of up to 60 min. For all tested condi-
tions, there was no effect of ubiquitin on intracellular cAMP levels
(Fig. S5B). (iii) Since we noticed slightly increased cAMP levels in
some ubiquitin treated samples compared to controls, we looked
at possible antagonistic effects of ubiquitin in the presence of
SDF-1. Therefore, 1 lM SDF-1 and ubiquitin in various concentra-
tions ranging from 1 to 10 lM were added simultaneously to
THP-1 cells and incubated for 15 min followed by cAMP ELISA. In
all tested concentrations ubiquitin had no antagonistic effect on
SDF-1 treated THP-1 cells (Fig. S5C).
To further support the acquired data concerning cAMP levels we
constructed a stable cell pool of 293T cells expressing the CXCR4
full length protein. Afterwards, we transiently transfected the cell
pool with a pGL4.29 reporter plasmid (Promega), designed to mon-
itor increases in cAMP levels through a cAMP response element
(CRE) that drives transcription of a luciferase reporter gene. We
stimulated cells with forskolin to non-speciﬁcally increase the
cAMP levels through activation of adenylate cyclase and added in
parallel different compounds to measure a change in lumines-
cence. As seen for the cAMP ELISA, SDF-1 was able to inhibit the
Fig. 4. Binding analysis and calcium signaling of ubiquitin on THP-1 and Jurkat cells. (A) Binding of 1 lM (left panel) or 10 lM (right panel) FITC-ubiquitin (R&D Systems)
with (red) or without (green) competition with 30-fold molar excess of unlabeled ubiquitin (Sigma) to THP-1 cells was assessed by ﬂow cytometry. Untreated cells are shown
in grey. (B) Binding of 1 lM (left panel) or 10 lM (right panel) FITC-ubiquitin (R&D Systems) with (red) or without (green) competition with 30-fold molar excess of unlabeled
ubiquitin (Sigma) to Jurkat cells was assessed by ﬂow cytometry. Untreated cells are shown in grey. (C and D) THP-1 (C) or Jurkat (D) cells were labelled with the Calcium 5
ﬂuorophore and incubated with different concentrations of SDF-1 or ubiquitin (Sigma). Increase in Calcium 5 signal intensity indicating calcium signaling was monitored in
the FlexStation 3 instrument. Error bars represent SEM of four (THP-1) and three (Jurkat) independent experiments.
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(F45W Scil Proteins) had no such effect (Fig. 5B). Similar as in
the cAMP ELISA in some cases there was rather a tendency for
slightly increased cAMP levels. This phenomenon was not concen-
tration dependent and an agonistic activity of ubiquitin has been
excluded with the ELISA. Additionally, we incubated the cells with
the well-known CXCR4 inhibitor AMD100 [87] prior to SDF-1 and
forskolin. This treatment resulted in a loss of activity of SDF-1 on
cAMP levels due to inhibition of the CXCR4 receptor, showing the
speciﬁcity of our assay (Fig. S5D). Furthermore, we compared dif-
ferent ubiquitin variants (F4A and V70A in Fig. S5D) or sources
(F45W ubiquitin and di-ubiquitin Scil Proteins, ubiquitin Sigma,
ubiquitin R&D Systems in Fig. S5E) but found no variation.
Hence, ubiquitin has no impact on cAMP levels in the cell lines
tested.
3.8. Inﬂuence of ubiquitin on IP3 levels
Next, we additionally investigated a different branch of the
GPCR signaling cascade. We co-transfected HEK293 and COS-7
cells transiently with CXCR4 and chimeric G-protein G
alphaD6qi4myr cDNA and labeled cells with 3H-myo-inositol. G
alphaD6qi4myr is a chimeric G-protein that switches CXCR4signaling from the G alpha i pathway to the G alpha q pathway
leading to release of inositol-3-phosphates (IP3) [88]. After suc-
cessful labeling cells were treated with SDF-1 or ubiquitin
(Sigma) for 2 h in the indicated concentrations and accumulation
of radioactively labeled IP3 was determined. In both cell lines
SDF-1 led to an increase in IP3 levels with an EC50 of 4 ± 1.4 nM
for HEK293 (Fig. 5C) and 1.6 ± 1.5 nM for COS-7 cells (Fig. 5D)
respectively. As in the previous assays ubiquitin had also no inﬂu-
ence on IP3 levels through a postulated activation of the CXCR4
receptor. Similar results were obtained in an experiment with
ubiquitin F45W from Scil Proteins (Fig. S6).
3.9. Effect of ubiquitin on cell migration
To verify our binding and signal transduction data with a more
physiologically relevant read-out we chose a cell migration assay.
THP-1 cells from two different suppliers or Jurkat cells were seeded
in the upper chamber of 96 HTS transwell plates (Corning) with
appropriate membrane pore sizes for the respective cell lines.
The lower chamber was loaded with different concentrations of
SDF-1 or ubiquitin (Sigma) and cell migration to the lower cham-
ber after 3 h was determined by FACS analysis. SDF-1 showed an
increase in the chemotactic index with speciﬁc kinetics for both
Fig. 5. Ubiquitin impact on the CXCR4 signaling cascade. (A) THP-1 cells were incubated with SDF-1 or ubiquitin (Sigma) in the indicated concentrations. cAMP content was
analyzed after cell lysis with the cAMP complete enzyme immunoassay kit, acetylated format for higher sensitivity. Error bars represent SEM of three independent
experiments. (B) HEK293 cells expressing CXCR4 were transfected with a pGL4.29 reporter plasmid and stimulated after 48 h with forskolin without (dark grey bar) or in
combination with SDF-1 (red bar) or ubiquitin (F45W Scil Proteins, blue bars) in indicated concentrations. Unstimulated cells (light grey bar) served as negative control. Data
were normalized on luciferase activity for forskolin treatment set to 100%. Error bars represent SD from three experiments. (C and D) HEK293 (C) or COS-7 (D) cells were
transiently transfected with CXCR4 and the chimeric G-protein G alphaD6qi4myr. Afterwards cells were labelled with 0.3 lCi 3H-myo-inositol for more than 16 h followed by
incubation with SDF-1 or ubiquitin (Sigma) in the indicated concentrations. Accumulated IP3 was collected by anion exchange chromatography from cell extracts followed by
a beta counter quantiﬁcation. Error bars represent SEM from three (HEK) or four (COS-7) independent experiments. (E and F) THP-1 (E) or Jurkat (F) cells were seeded in the
upper compartment of 96 HTS transwell plate chambers. The lower compartment was ﬁlled with PBS containing indicated concentrations of SDF-1 or ubiquitin (Sigma). After
3 h incubation cells in the lower chamber were collected and analyzed by ﬂow cytometry. Chemotactic index was calculated as the ratio of the number of migrated cells at the
indicated ligand concentration to the number of cells migrated to buffer. Error bars represent SEM from three independent experiments.
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towards ubiquitin (Fig. 5E and F) in the tested, broad concentration
range.
From all these in vitro experiments we conclude that ubiquitin
induces no CXCR4 signaling in the tested lymphocytes or otherCXCR4 overexpressing cell lines and had no effect on their migra-
tory behavior. This result ﬁts well to the in vivo data presented,
as even very high concentrations of in vivo applied ubiquitin did
not induce any signiﬁcant biological activity, especially not any
CXCR4-related reactions, in treated mice.
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Ubiquitin is a naturally stable, fast folding protein. To ﬁnally
exclude any doubt about the biological activity and equivalence
of the ubiquitin species from different sources used in our work
we performed ubiquitination studies (Fig. S7). A commercially
available substrate and coupling kit was used for ligation reactions
with monomeric ubiquitin from the R&D Systems’ kit components,
ubiquitin separately purchased from R&D Systems, ubiquitin pur-
chased from Sigma and our in house produced F45W ubiquitin.
Linear dimeric ubiquitin was run in parallel, again from R&D
Systems and in house production. All monomeric ubiquitin prepa-
rations were very efﬁciently coupled to the substrate. Marginal
deviations in the intensity of the detected bands can be correlated
with the slightly ﬂuctuating substrate amounts contained in the
individual reactions and loaded on the gel. The phenomenon is
due to technical features of the experiment and it has been
repeated for conﬁrmation with the same result. Ubiquitination
with the dimeric forms was weaker as with the monomeric ones
but again very similar among the two tested species.
4. Discussion
Ubiquitin is a highly abundant, omnipresent molecule in mam-
malian organisms. It exerts innumerable effects mainly inside the
cell but is also present in the extracellular compartment. Its versa-
tility is based on the many possible non-covalent and covalent
interaction options. Ubiquitin occurs as monomer or multimer of
diverse composition concerning numbers or type(s) of linkage of
ubiquitin entities. The typical ubiquitin interaction has KD values
in the high nanomolar to lowmicromolar range. Speciﬁcity is given
by compartmentalization or characteristics of the respective ubiq-
uitin species.
The choice of (di)ubiquitin as scaffold for the generation of
binding molecules with new properties for therapeutic application
irrespective of the natural ubiquitin targets requires that the above
described functions are unaffected by such compounds. A different
or complementary ubiquitin based therapeutic approach was
published by the Sidhu group, selecting ubiquitin variants after
randomization of up to 19 amino acid positions as possible
modulating agents for intrinsic ubiquitin targets [89]. The
presented work scrutinizes the mandatory inertness or at least
innoxiousness of ubiquitin as parenteral drug. In this context the
recently published ﬁnding that ubiquitin is a hitherto unknown
ligand of the chemokine receptor CXCR4 [48–50,76,77] is relevant
and therefore investigated in depth.
Irrespective of our in vitro ﬁndings related to a postulated speci-
ﬁc ubiquitin CXCR4 interaction, the general impact of high ubiqui-
tin doses applied to the organism has been tested thoroughly in
in vivo studies. Biodistribution experiments were performed with
radio labeled proteins in the Wistar rat and CD1 mouse model.
Distribution of radio labeled ubiquitin intravenously injected into
Wistar rats did not provide any evidence for a speciﬁc ubiquitin
accumulation in main organs, except the kidneys. Comparable data
were obtained after intravenous administration of radio labeled
di-ubiquitin into mice. After initial distribution into highly per-
fused organs like liver, spleen, lungs and gastrointestinal tract
the proteins are quickly cleared from the circulation and from
organs revealing organ/blood ratios <1. Ubiquitin and
di-ubiquitin are small proteins sized below the glomerular ﬁltra-
tion threshold. The normal pathway of elimination of proteins of
this size is expected to be ﬁltration in the glomerulus and subse-
quent reabsorption in the proximal tubules by means of endocyto-
sis followed by lysosomal degradation. The high radioactivity
detected in the kidneys at indicated time points and theaccumulation within urine at 16 h post-injection point to the renal
elimination as main route for clearance of ubiquitin and
di-ubiquitin. Due to the quick renal clearance of ubiquitin a short
half-life of 23.6 min was determined in mice. A similar fast blood
clearance was observed for di-ubiquitin with approximately 7%
of injected radioactivity measured in blood as early as 5 min
post-injection. These data are well comparable to already pub-
lished information on ubiquitin half-life [42,75].
While numerous physiological functions for intracellular ubiq-
uitin species are reported, a physiological function of extracellular
ubiquitin as contained in serum is so far not described. Recently, an
interaction of extracellular ubiquitin with CXCR4 (in the range of
KD 100 nM) has been reported [47–50]. The CXCR4 receptor is
expressed in almost all blood cells [47,90–93]. The basal ubiquitin
serum level in mice was determined at 24.0 ng/ml corresponding
to an ubiquitin concentration of 2.8 nM, which is similar to the
human serum ubiquitin level with a mean concentration of
32.7 ng/ml [32]. This ubiquitin serum concentration is more than
one order of magnitude below the KD for the postulated ubiquitin
CXCR4 interaction. However, administration of ubiquitin may lead
to an increase to values around or above the KD of a putative
ubiquitin-CXCR4 interaction [37,51,77]. Five min after application
of 0.2 mg/kg ubiquitin and 0.1 mg/kg di-ubiquitin serum levels of
50 and 20 nM are obtained, respectively. Concentrations of
500 nM were reached post-injection of 3 mg/kg di-ubiquitin.
Although protein concentrations sufﬁcient for protein internaliza-
tion or physiologically relevant signals are available within the ﬁrst
minutes, our data on ex vivo analysis of blood and related serum
samples do not support an uptake of ubiquitin into total blood
cells. Moreover, radioactivity measured in spleen, the largest lym-
phoid organ with storage function for lymphocytes and monocytes
[94], did not provide evidence for accumulation of ubiquitin.
Therefore, the published data on ubiquitin-CXCR4 interaction
obtained in in vitro experiments are not conﬁrmed by a detectable
ubiquitin accumulation in CXCR4 expressing cells or tissues under
healthy conditions. One point that should be taken into account in
this context is the rapid clearance and thus limited availability of a
sufﬁcient high ubiquitin concentration within the bloodstream.
Ubiquitin did not show toxic effects in reports from healthy and
disease models in different animal species [41,42,74,75].
Application of ubiquitin was generally performed at a single low
dose of between 1 and 3 mg/kg in these studies. Ubiquitin of all
mammalian species investigated so far shares 100% sequence iden-
tity, which means freedom of choice regarding a relevant animal
model. We selected the Wistar rat model for further toxicological
evaluation of ubiquitin and di-ubiquitin. Rat CXCR4 shows 90%
sequence identity and 96% sequence homology compared to
human qualifying this species as relevant for these studies.
Intravenous administration of up to 100 mg/kg of di-ubiquitin in
an acute setting and repeated dosing of 3 mg/kg of ubiquitin in a
subacute setting did not elicit any evidence for toxic effects.
Moreover, no alterations of numbers of CXCR4 expressing blood
cells were detected. Thus, for instance lymphocyte release from
the spleen rapidly increasing the blood cell pool or cell depletion
e.g. by diapedesis induced by inﬂammatory reactions do not occur.
In addition, the endogenous level of several pro-inﬂammatory
cytokines known to interfere with the regulation of CXCR4 [95–
97] were not inﬂuenced by ubiquitin treatment.
To complement the assessment of ubiquitin or di-ubiquitin
application in vivo, we were interested in the hypothesis of their
direct interaction with CXCR4 in more detail. Indeed, we could
detect some binding of FITC-labeled ubiquitin to CXCR4 expressing
cell lines like THP-1 or Jurkat. This interaction was weak though
and occurred only at high concentrations of up to 10 lM, much
higher than expected for a binder with 100 nM afﬁnity [47].
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molar excess of unlabeled ubiquitin. We therefore consider this
phenomenon as non-speciﬁc and unrelated to the actual presence
of CXCR4. This was further conﬁrmed in the comparison of CXCR4
transfected to non-transfected HEK293 cells. Binding of labeled
ubiquitin to cells, namely platelets has also shown by Tan and col-
leagues [98]. Unfortunately the speciﬁcity of that effect has not
been proven by competition with unlabeled ubiquitin. On the other
hand uptake of a ubiquitin mutant fused to a BH3 peptide has been
found and hypothesized to be mediated via the CXCR4 axis [38]. As
this molecule deviates markedly from wild type ubiquitin not only
in the primary sequence (K48R/K63R) but also by attached linker,
BH3 and tag domains the mechanism of its uptake is not clearly
elucidated. The presumably speciﬁc uptake could for example only
be inhibited by very high amounts of ubiquitin as competitor.
Recent papers discussing the structural basis of CXCR4 modulation
do not imply the concept of ubiquitin being a ligand of the receptor
[99,100].
To pursue the possibility for a notwithstanding signaling at very
low receptor occupancies [101,102] we decided to inspect different
aspects from the complex signaling network of CXCR4. Although
the chemokine receptors are predominantly coupled to G alpha i,
a known and frequently used indicator of receptor activity is an
increase of free intracellular calcium. This response to ligand bind-
ing is probably elicited via the G beta-gamma subunits. As these
calcium ﬂuxes have a very fast kinetic an appropriate automated
set up for exact real time measurements is mandatory. Moreover,
manual handling often leads to artefacts like stretch activated cal-
cium inﬂux or instability through uneven mixing. We therefore
used the Flex station 3 instrument for our analyses. With this reli-
able method a concentration dependent rise of calcium levels after
CXCR4 stimulation with SDF-1 was observed in THP-1 and also in
Jurkat cells. In clear contrast, ubiquitin, although tested several
times and at high concentrations, did not show any response in
the calcium ﬂux assay. This contradicts the results of Saini et al.
[49] but might be due to the different data acquisition.
As an independent criterion we analyzed inhibition of cAMP
accumulation. We used a commercially available ELISA and
THP-1 cells. SDF-1 led to a drop in cAMP levels, whereas ubiquitin
had no such effect. In order to identify a source for the deviation
from the data of Saini et al. [49] several controls were performed.
THP-1 from a second supplier behaved exactly in the same way.
In addition, we generated stable cell pools expressing the CXCR4
receptor in HEK293. These pools were transiently transfected with
a reporter gene to monitor cAMP. SDF-1 showed speciﬁc inhibition,
which could be blocked by AMD3100, while ubiquitin did not
impair cAMP synthesis. No effects of addition of anti CXCR4 anti-
bodies to epitopes in the postulated ubiquitin binding site or
AMD3100 could be seen. The characteristic inhibitory signaling
cascade was not initiated by any ubiquitin concentration or resi-
dence time. Results from several ubiquitin variants were in line
with these conclusions. In some experiments we rather noticed a
tendency for a slight increase of the cAMP levels after ubiquitin
incubation. The phenomenon was not concentration dependent.
Signiﬁcance of or the mechanism responsible for this is specula-
tive. A possible CXCR4 speciﬁc antagonistic effect was experimen-
tally excluded.
The functional measurement of inhibitory G-proteins is
somewhat challenging because the optimal timing of the
activation–inhibition process is not fully understood. The order and
time intervals of the treatment with the different compounds like
forskolin and the ligand and/or inhibitor under investigation are
not obvious and have to be individually established. For this reason
a third independent route of second messengers was pursued. As
a classical component in the GPCR downstream cascade, accumu-
lation of inositol-3-phosphate was monitored in cells transfectedwith a chimeric G-protein switching G alpha i to G alpha q sig-
naling. To broaden the approach, these analyses were performed
in HEK293 and in COS-7 cells. Again, SDF-1 treatment led to the
concentration dependent and saturable rise in intracellular IP3
while application of ubiquitin failed to evoke a detectable IP3
signal.
For a ﬁnal attempt a more universal terminal signal of G alpha i
activation was chosen, that is chemotaxis. Chemotaxis is a central
mechanism for CXCR4 function involved in physiological and
pathophysiological processes like stem cell homing, wound healing
and metastasis. It is induced via different branches of the CXCR4
intracellular cascade. Therefore, independent of potential diversity
in cell types or assay speciﬁcities, cell migration should be a gen-
eral consequence of CXCR4 receptor activation. THP-1 and Jurkat
cells were used in transwell experiments. SDF-1 showed the typi-
cal bell-shaped curves in the activation assay while ubiquitin did
not initiate cell migration at all. Chemotactic activity of ubiquitin
was observed on B16-F10, 4T1 and RM-9 cells as described in the
literature [51]. A direct interaction of ubiquitin on CXCR4 has not
been shown in this work.
In addition to the variation of aspects, assays and cell types we
involved in our studies, different ubiquitin preparations from com-
mercial sources and in house production were included. Relevant
experiments were conducted with the Sigma ubiquitin used for
the recently published CXCR4 studies, some of them also with
ubiquitin from one or more other sources. Finally all species were
enclosed in a ubiquitination assay showing equal bioactivity of the
tested monomeric and dimeric forms respectively. This should
exclude the notion, ubiquitin from variable sources might behave
differently in a biological context.
Thus, in spite of applying a diverse set of assays, the hypothesis
of ubiquitin being a ligand for CXCR4 could not be proven. There
was not a faint tendency for effectiveness in any experiment. The
function of known chemokines and their receptors usually implies
a speciﬁc and high afﬁnity interaction while ubiquitin is known for
weak interactions at usually high concentrations in vivo, at least in
the context of intracellular functions. In our hands, there is no
evidence for ubiquitin-induced signaling through a sensitive
chemokine receptor such as CXCR4. We have taken much effort
to exclude variations in assay conditions and to include a represen-
tative set of cell lines and consistently found no activation. The
effects of high doses or levels of ubiquitin and those of CXCR4 acti-
vation in the organism might be similar, but probably not directly
interconnected. It could well be that CXCR4 is part of a more com-
plex network of mechanisms where ubiquitin is also involved. For
example transactivation events, receptor internalization and mem-
brane plasticity are inﬂuenced by ubiquitin in general. Very current
reports show compelling evidence for the ubiquitin dependent sig-
naling and trafﬁcking of CXCR4 without the assumption of a
ligand–receptor complex formation [103–105]. This ﬁts well into
the known functions and regulation of chemokine receptors and
ubiquitin alike. Surprising ﬁndings like the disruption of the
SDF-1/CXCR4 axis by IL-24 [106] or the antagonism of a serum
albumin fragment [107] show that our idea of possible underlying
interconnections is far from being complete. The pathways, which
lead to the observed and published effects and the physiological
consequences in the interplay of ubiquitin and CXCR4 have to be
further elucidated.5. Conclusion
With the presented data the safety of ubiquitin as a scaffold for
the development of therapeutic binding molecules has been under-
pinned in detail and in general. A speciﬁc binding of ubiquitin to
CXCR4 or activation of the receptor could be experimentally
F. Job et al. / FEBS Open Bio 5 (2015) 579–593 591excluded. Adverse or unfavorable reactions after in vivo adminis-
tration were not seen even at high doses.
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